<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-27807" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Acute Promyelocytic Leukemia</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Cingam</surname>
            <given-names>Shashank R.</given-names>
          </name>
          <aff>University of New Mexico Comprehensive Cancer Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Koshy</surname>
            <given-names>Nebu V.</given-names>
          </name>
          <aff>Louisiana State University HSC</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Shashank Cingam declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Nebu Koshy declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>26</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-27807.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Acute promyelocytic leukemia is a distinguished subset of acute myeloid leukemia which is characterized by fusion gene transcript PML-RAR-alpha and high cure rates with treatment. This entity was first described in 1957 in patients with severe bleeding tendencies, fibrinolysis, rapid deterioration of the clinical status, and presence of promyelocytes in peripheral blood and bone marrow. This activity illustrates the presentation, evaluation, and management of patients with promyelocytic leukemia and highlights the role of the interprofessional team in caring for patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology of acute promyelocytic leukemia.</p></list-item><list-item><p>Outline the presentation of a patient with acute promyelocytic leukemia.</p></list-item><list-item><p>Describe the treatment options available for acute promyelocytic leukemia.</p></list-item><list-item><p>Summarize interprofessional team strategies for improving care coordination and communication to advance the diagnosis and treatment of acute promyelocytic leukemia and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27807&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27807">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-27807.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Acute promyelocytic leukemia is a distinguished subset of acute myeloid leukemia which is characterized by fusion gene transcript PML-RAR-alpha and high cure rates with treatment. This entity was first described in 1957 in patients with severe bleeding tendencies with fibrinolysis, rapid deterioration of the clinical condition, and the presence of promyelocytes in peripheral blood and bone marrow.<xref ref-type="bibr" rid="article-27807.r1">[1]</xref><xref ref-type="bibr" rid="article-27807.r2">[2]</xref><xref ref-type="bibr" rid="article-27807.r3">[3]</xref></p>
        <p>Advances in the molecular pathology of this leukemia have led to the introduction of arsenic trioxide and all-trans retinoic acid therapies, which have led to improved prognosis.</p>
      </sec>
      <sec id="article-27807.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The <italic toggle="yes">RAR-alpha (Retinoic acid-alpha)</italic> gene which encodes nuclear hormone receptor transcription factors is present on the long arm of chromosome 17 and is invariably involved in APL. It promotes the expression of various genes after binding to retinoic acid. In majority (90% to 95%) of the cases, APL results from a t (15;17) (q22;q21) translocation resulting in the head to tail fusion of the&#x000a0;<italic toggle="yes">promyelocytic leukemia</italic>&#x000a0;(<italic toggle="yes">PML</italic>) gene, to&#x000a0;<italic toggle="yes">RAR-alpha</italic>&#x000a0;to generate two fusion genes,&#x000a0;<italic toggle="yes">PML</italic>-<italic toggle="yes">RARalpha</italic>&#x000a0;and a reciprocal <italic toggle="yes">RAR-alpha-PML&#x000a0;</italic>(80%) that encode a protein, which functions as an aberrant retinoid receptor.&#x000a0;The other cytogenetic abnormalities associated with APL include t(5;17)(q35;q21), t(11;17)(q23;q21), t(11;17)(q13;q21), and t(17;17)(q11;q21) fuse RAR-alpha to the <italic toggle="yes">Nucleophosmin</italic>&#x000a0;(<italic toggle="yes">NPM</italic>),&#x000a0;<italic toggle="yes">Promyelocytic Leukemia Zinc Finger</italic>&#x000a0;(<italic toggle="yes">PLZF</italic>),&#x000a0;<italic toggle="yes">Nuclear Mitotic Apparatus&#x000a0;</italic>(<italic toggle="yes">NuMA</italic>), and&#x000a0;<italic toggle="yes">STAT5b</italic>&#x000a0;genes, respectively, leading to expression of their fusion proteins. These translocations also have clinical significance due to their responsiveness (NPM/RAR-alpha, NuMA/RAR-alpha) or partial/complete refractoriness to retinoids (STAT5B/RAR-alpha, PLZF/RAR-alpha).<xref ref-type="bibr" rid="article-27807.r4">[4]</xref><xref ref-type="bibr" rid="article-27807.r5">[5]</xref></p>
        <p>The mechanisms of formation of the above chromosomal rearrangements and initiation of the leukemia are unknown. Chemotherapy, ionizing radiation, industrial solvents, and other toxic agents are some of the known risk factors.&#x000a0;</p>
      </sec>
      <sec id="article-27807.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Acute promyelocytic leukemia is a relatively rare and comprises about 7% to 8% of adult AML cases.&#x000a0;Acute promyelocytic leukemia&#x000a0;is usually seen in middle-aged people with a median age of 47 years. Acute promyelocytic leukemia&#x000a0;occurs very rarely before the age of 20. The incidence is slightly higher in males than in females.</p>
      </sec>
      <sec id="article-27807.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The&#x000a0;PML/RARa&#x000a0;protein heterodimerizes with the retinoid X receptor (RXR), the resulting&#x000a0;PML/RARa-RXR&#x000a0;complex binds to retinoic acid-responsive elements in target genes,&#x000a0;resulting in cessation of myeloid differentiation at the promyelocytic stage. The excessive promyelocytes&#x000a0;express tissue factor (TF) which forms a complex with factor VII and activates factor X and IX and result in a pro-coagulant state. The immature promyelocytes also cannot build defenses against infections, rendering patients immunosuppressed.<xref ref-type="bibr" rid="article-27807.r6">[6]</xref><xref ref-type="bibr" rid="article-27807.r7">[7]</xref></p>
        <p>There are also certain fusions that make this leukemia insensitive to retinoic acid and chemotherapy.</p>
      </sec>
      <sec id="article-27807.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Acute promyelocytic leukemia&#x000a0;is characterized by the presence of the large atypical promyelocytes and other myeloid precursors in various stages of development in the peripheral blood. The bone marrow is hypercellular, and APL promyelocytes account for about 30% of the myeloid cells in the classic variant. The typical acute promyelocytic leukemia&#x000a0;promyelocyte has a creased, folded, bilobed, kidney-shaped, or dumb-bell shaped nuclei with a high nucleus-cytoplasmic ratio, fine chromatin, and prominent nucleoli, in addition to many violet granules (which coalesce to form Auer rods) in the cytoplasm and intense myeloperoxidase activity. In the microgranular variant (20% to 30%), pellets and Auer rods are less prominent, and the nucleus has a characteristic bilobed, folded appearance. Other less common variants, hyperbasophilic variant, M3r (associated with the&#x000a0;<italic toggle="yes">PLZF</italic>) have also been described in the literature.</p>
        <p>On immunophenotyping, the premature malignant promyelocytes express bright cytoplasmic myeloperoxidase, early myeloid markers, CD13 and CD33 but do not express HLA-DR, CD11b and are weakly positive/negative for CD15, CD117 (expressed in mature myelocytes) and CD34 (early myeloid progenitor cells). CD9 is expressed in&#x000a0;acute&#x000a0;promyelocytic leukemia&#x000a0;but not in other AML subtypes. Co-expression of CD 2 is commonly seen in the hypogranular variant of acute promyelocytic leukemia.</p>
      </sec>
      <sec id="article-27807.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Patients usually present with generalized weakness and fatigue, gingival bleeding, petechiae or ecchymoses, visual changes secondary to retinal hemorrhages, epistaxis, or menorrhagia or infections. Patients may also present with thrombotic complications such as deep venous thrombosis, pulmonary embolism, cerebrovascular accident, etc. Some patients with advanced disease may present with overt disseminated intravascular coagulation and frank bleeding.</p>
        <p>Pancytopenia is common at presentation. The key difference between APL and AML is that many patients with the former ae at risk for disseminated intravascular coagulation and associated hyperfibrinolysis. The coagulopathy has to be managed as a medical emergency otherwise it often leads to CNS and pulmonary hemorrhage.</p>
      </sec>
      <sec id="article-27807.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>When&#x000a0;acute&#x000a0;promyelocytic leukemia&#x000a0;is suspected, evaluation of peripheral blood smear and FISH for the fusion of PML/RARA should be expedited for rapid diagnosis of this time-sensitive disease. A prompt coagulopathy workup including a platelet count, prothrombin time (PT), activated partial thromboplastin time (PTT), d-dimer or fibrin split products, and fibrinogen should also be performed. Bone marrow biopsy and immunophenotyping should also be performed. Conventional karyotyping should also be performed as a part of initial workup as it detects rare molecular subtypes of&#x000a0;acute&#x000a0;promyelocytic leukemia&#x000a0;and other additional coexistent cytogenetic abnormalities- t(15:17). Reverse transcriptase-polymerase chain reaction (RT-PCR) for PML-RARA RNA is also used for confirming the diagnosis of&#x000a0;acute&#x000a0;promyelocytic leukemia&#x000a0;and can also be used can for monitoring minimal residual disease.</p>
        <p>Acute&#x000a0;promyelocytic leukemia&#x000a0;is classified into low-risk (white blood cell count (WBC) 10,000/microL or less and platelets 40,000/microL or more), intermediate (WBC 10,000/microL or less and platelets 40,000/microL or less), and high-risk (WBC more than 10,000/microL) to guide treatment.<xref ref-type="bibr" rid="article-27807.r8">[8]</xref><xref ref-type="bibr" rid="article-27807.r9">[9]</xref><xref ref-type="bibr" rid="article-27807.r10">[10]</xref><xref ref-type="bibr" rid="article-27807.r11">[11]</xref></p>
        <p>Lumbar puncture is done in high-risk patients with elevated WBC count if intrathecal therapy is contemplated. Further, a cardiac evaluation is necessary before administering anthracyclines.</p>
      </sec>
      <sec id="article-27807.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>
<bold>Chemotherapy</bold>
</p>
        <p>Acute&#x000a0;promyelocytic leukemia&#x000a0;is a medical emergency with a very high pre-treatment mortality. All-Trans Retinoic Acid (ATRA) is the mainstay in the treatment of&#x000a0;acute&#x000a0;promyelocytic leukemia&#x000a0;and used in all modern regimens. ATRA should be initiated without any delay even before cytogenetic confirmation is obtained. Before the introduction of ATRA in the 1980s, the prognosis of this disease was poor with chemotherapy alone. ATRA was then used in combination with anthracycline-based regimens with increased survival and cure rate. ATO (arsenic trioxide)&#x000a0;also induces differentiation of the malignant myeloid clone by dissociating the&#x000a0;PML/RAR-alpha-RXR&#x000a0;complex from the target genes and found to have a synergistic action with ATRA. ATRA-ATO was also shown to have comparatively lesser toxicities than ATRA-chemo. Hence, ATRA-ATO for induction and consolidation has emerged as the new standard of care for patients with low-(to-intermediate) risk&#x000a0;acute&#x000a0;promyelocytic leukemia. ATRA- Idarubicin or ATRA - ATO plus gemtuzumab ozogamicin (antibody-drug conjugate) are preferred in patients with high risk without cardiac dysfunction. ATRA-ATO therapy with or without gemtuzumab ozogamicin&#x000a0;is also a reasonable choice for patients with severe comorbidities, older adults, patients with cardiac dysfunction who cannot tolerate anthracycline-based regimens or overall poor functional status. Maintenance therapy after the initial consolidation is widely debated. Maintenance may not be necessary&#x000a0;for patients receiving intensive induction/consolidation including ATO. Treatment and post-treatment monitoring up to 2 years with PCR are recommended. Treatment of relapsed APL is beyond the scope of this article.</p>
        <p><bold>Supportive Therapy</bold>&#x000a0;</p>
        <p>Supportive therapy plays a very important role in the survival of patients with acute leukemia. Bleeding diathesis is a known complication, especially in patients receiving treatment and platelets, should be maintained above 30 to 50 &#x000d7; 10/l and fibrinogen above 100&#x000a0;mg/dl&#x000a0;to 150 mg/dl, with aggressive blood product support. High suspicion should be maintained for systemic infections as the patients are routinely immunosuppressed. In granulocytopenic patients with fever, an empiric antibiotic regimen to treat gram-negative bacteria should be instituted. Vancomycin should be started, if there is suspicion of catheter-related infection or based on blood cultures or if there is a suspicion of severe unknown infection. Antifungal should be considered if fever persists 5 days after the initiation of empiric antibiotics with appropriate testing.</p>
        <p>Because cure rates for APL are high, bone marrow transplantation is not the first option. It is only offered to patients who relapse or are resistant to therapy.</p>
        <p>Intrathecal therapy is done in high-risk patients.</p>
      </sec>
      <sec id="article-27807.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Acute lymphoblastic leukemia (ALL)</p>
          </list-item>
          <list-item>
            <p>Acute myeloid leukemia (AML)</p>
          </list-item>
          <list-item>
            <p>Aplastic anemia</p>
          </list-item>
          <list-item>
            <p>Folic acid deficiency</p>
          </list-item>
          <list-item>
            <p>Myelodysplastic syndrome</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27807.s11" sec-type="Toxicity and Adverse Effect Management">
        <title>Toxicity and Adverse Effect Management</title>
        <p>Arsenic trioxide can cause prolonged QT and hepatotoxicity. Chemotherapy containing regimens cause cytopenias, increased risk of infections, mucositis.&#x000a0;<bold>Idiopathic intracranial hypertension or pseudotumor cerebri</bold> is a known complication of retinoic acid derivatives. It is characterized by headaches, papilledema, increased intracranial pressure and improvement with a lumbar puncture. Steroids, acetazolamide, and analgesics can be used in patients with persistent symptoms.</p>
      </sec>
      <sec id="article-27807.s12" sec-type="Medical Oncology">
        <title>Medical Oncology</title>
        <p>Guidelines</p>
        <list list-type="order">
          <list-item>
            <p>Immediately admit patient, initiate ATRA and manage the coagulopathy</p>
          </list-item>
          <list-item>
            <p>Confirm the diagnosis</p>
          </list-item>
          <list-item>
            <p>Monitor coagulation parameters</p>
          </list-item>
          <list-item>
            <p>Start transfusions until coagulation parameters are normalized</p>
          </list-item>
          <list-item>
            <p>Start therapy with ATRA</p>
          </list-item>
          <list-item>
            <p>Perform bone marrow assessment to determine the response</p>
          </list-item>
          <list-item>
            <p>Continue ATRA therapy until there is clinical benefit</p>
          </list-item>
          <list-item>
            <p>Combine ATRA with chemotherapy in patients who relapse</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27807.s13" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis of APL is very poor without treatment (median survival~1 month). However, with modern treatment, survival has improved greatly and most patients achieve complete remission and remain so. In the Lo-coco<xref ref-type="bibr" rid="article-27807.r12">[12]</xref>&#x000a0;study,&#x000a0;the 2-year disease-free survival rate was 97% (95% CI, 94 to 100) in the ATRA&#x02013;arsenic trioxide group and 90% (95% CI, 84 to 97) in the ATRA&#x02013;chemotherapy group (P=0.11).&#x000a0;</p>
        <p>Without treatment, death is inevitable due to infection and hemorrhagic differentiation syndrome. The WBC count is an indicator of prognosis; high counts are associated with high risk. Other factors that affect prognosis include advanced age, male gender, elevated serum creatinine, and fibrinogen levels.</p>
      </sec>
      <sec id="article-27807.s14" sec-type="Complications">
        <title>Complications</title>
        <p><bold>Differentiation Syndrome</bold> is a cytokine release syndrome seen after initiation of differentiating agents characterized by&#x000a0;fever, peripheral edema, pulmonary edema, multiorgan dysfunction which can be fatal, if not promptly recognized. High dose systemic steroids are helpful in these cases.</p>
        <p><bold>Hyper Leukocytosis</bold> can occur as a complication of differentiation agents due to rapid differentiation of immature promyelocytes. Systemic steroids and chemotherapy are used in severe cases.</p>
      </sec>
      <sec id="article-27807.s15" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>A neutropenic diet is recommended with no flowers or fresh fruit to be in the room.</p>
        <p>Patients should be monitored for thrombocytopenia and spontaneous bleeding.</p>
      </sec>
      <sec id="article-27807.s16" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>APL is a medical emergency best managed by an interprofessional team that includes an internist, intensivist, oncologist and a hematologist as well as a specialty-trained oncology nurse, dietician, and oncologic pharmacist. These patients need close monitoring by the oncology nurses as they are prone to bleeding diathesis, infections, multiorgan failure, and death. The nurse should immediately report any untoward findings to the clinical team. Due to the complexity of pharmacologic therapy, the oncology pharmacist should reconcile drugs and check for interactivity. Should there be concernings, they should address this with the attending clinician. The patient should be seen by a dietitian as a neutropenic diet is necessary. Further, the nurses should ensure that the patient's room is free of flowers and that visitors do not bring in any fruits. Clinicians should monitor the platelet count and observe for spontaneous bleeding. Prior to intrathecal therapy, the pharmacist should double-check the dose and duration of the drugs.</p>
        <p>The outlook for patients with APL is guarded but improved with the help of an interprofessional team managing the patient.&#x000a0;<xref ref-type="bibr" rid="article-27807.r13">[13]</xref></p>
      </sec>
      <sec id="article-27807.s17">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27807&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27807">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/cancer/acute-promyelocytic-leukemia/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=27807">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/27807/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=27807">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-27807.s18">
        <title>References</title>
        <ref id="article-27807.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title><italic>MLL</italic>-rearrangement can resemble acute promyelocytic leukemia.</article-title>
            <source>Leuk Lymphoma</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>60</volume>
            <issue>11</issue>
            <fpage>2841</fpage>
            <page-range>2841-2843</page-range>
            <pub-id pub-id-type="pmid">31038019</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27807.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ammatuna</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Huls</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Multidimensional radar dot-plots, do we need it for the screening of acute promyelocytic leukemia?</article-title>
            <source>Ann Hematol</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>98</volume>
            <issue>7</issue>
            <fpage>1793</fpage>
            <page-range>1793-1794</page-range>
            <pub-id pub-id-type="pmid">31025159</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27807.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hai</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Speciation analysis of arsenic in urine samples from APL patients treated with single agent As<sub>2</sub>O<sub>3</sub> by HPLC-HG-AFS.</article-title>
            <source>J Pharm Biomed Anal</source>
            <year>2019</year>
            <month>Jul</month>
            <day>15</day>
            <volume>171</volume>
            <fpage>212</fpage>
            <page-range>212-217</page-range>
            <pub-id pub-id-type="pmid">31009876</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27807.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Teng</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Cao</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tian</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nie</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>A novel NPM1-RARG-NPM1 chimeric fusion in acute myeloid leukaemia resembling acute promyelocytic leukaemia but resistant to all-trans retinoic acid and arsenic trioxide.</article-title>
            <source>Br J Cancer</source>
            <year>2019</year>
            <month>May</month>
            <volume>120</volume>
            <issue>11</issue>
            <fpage>1023</fpage>
            <page-range>1023-1025</page-range>
            <pub-id pub-id-type="pmid">30996344</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27807.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yan</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yin</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>RNF8 is responsible for ATRA resistance in variant acute promyelocytic leukemia with GTF2I/RARA fusion, and inhibition of the ubiquitin-proteasome pathway contributes to the reversion of ATRA resistance.</article-title>
            <source>Cancer Cell Int</source>
            <year>2019</year>
            <volume>19</volume>
            <fpage>84</fpage>
            <pub-id pub-id-type="pmid">30992691</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27807.r6">
          <label>6</label>
          <element-citation publication-type="book">
            <collab>PDQ Pediatric Treatment Editorial Board</collab>
            <chapter-title>Childhood Acute Myeloid Leukemia Treatment (PDQ&#x000ae;): Health Professional Version</chapter-title>
            <source>PDQ Cancer Information Summaries [Internet]</source>
            <publisher-name>National Cancer Institute (US)</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2024</year>
            <month>9</month>
            <day>16</day>
            <pub-id pub-id-type="pmid">26389454</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27807.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gong</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>MicroRNA-204 Potentiates the Sensitivity of Acute Myeloid Leukemia Cells to Arsenic Trioxide.</article-title>
            <source>Oncol Res</source>
            <year>2019</year>
            <month>Sep</month>
            <day>23</day>
            <volume>27</volume>
            <issue>9</issue>
            <fpage>1035</fpage>
            <page-range>1035-1042</page-range>
            <pub-id pub-id-type="pmid">30982490</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27807.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Strickland</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Shaver</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Byrne</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Daber</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Ferrell</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Head</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Mohan</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Mosse</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Moyo</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Stricker</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Vnencak-Jones</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Savona</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Seegmiller</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia.</article-title>
            <source>Leuk Res</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>65</volume>
            <fpage>67</fpage>
            <page-range>67-73</page-range>
            <pub-id pub-id-type="pmid">29310020</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27807.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Donnell</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Tallman</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Abboud</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Altman</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Appelbaum</surname>
                <given-names>FR</given-names>
              </name>
              <name>
                <surname>Arber</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Attar</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Borate</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Coutre</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Damon</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Lancet</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Maness</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Marcucci</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Millenson</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>JO</given-names>
              </name>
              <name>
                <surname>Ravandi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Shami</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Strickland</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Gregory</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Naganuma</surname>
                <given-names>M</given-names>
              </name>
              <collab>National Comprehensive Cancer Network</collab>
            </person-group>
            <article-title>Acute myeloid leukemia, version 2.2013.</article-title>
            <source>J Natl Compr Canc Netw</source>
            <year>2013</year>
            <month>Sep</month>
            <day>01</day>
            <volume>11</volume>
            <issue>9</issue>
            <fpage>1047</fpage>
            <page-range>1047-55</page-range>
            <pub-id pub-id-type="pmid">24029121</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27807.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Appelbaum</surname>
                <given-names>FR</given-names>
              </name>
              <name>
                <surname>Baer</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Carabasi</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Coutre</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Erba</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Estey</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Glenn</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Kraut</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Maslak</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Millenson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Saba</surname>
                <given-names>HI</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tallman</surname>
                <given-names>MS</given-names>
              </name>
              <collab>National Comprehensive Cancer Network</collab>
            </person-group>
            <article-title>NCCN Practice Guidelines for Acute Myelogenous Leukemia.</article-title>
            <source>Oncology (Williston Park)</source>
            <year>2000</year>
            <month>Nov</month>
            <volume>14</volume>
            <issue>11A</issue>
            <fpage>53</fpage>
            <page-range>53-61</page-range>
            <pub-id pub-id-type="pmid">11195419</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27807.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Iland</surname>
                <given-names>HJ</given-names>
              </name>
            </person-group>
            <article-title>Curative strategies in APL.</article-title>
            <source>Semin Hematol</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>56</volume>
            <issue>2</issue>
            <fpage>131</fpage>
            <page-range>131-138</page-range>
            <pub-id pub-id-type="pmid">30926089</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27807.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lo-Coco</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Avvisati</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Vignetti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Thiede</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Orlando</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Iacobelli</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ferrara</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Fazi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cicconi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Di Bona</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Specchia</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sica</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Divona</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Levis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fiedler</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Cerqui</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Breccia</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fioritoni</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Salih</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Cazzola</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Melillo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Carella</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Brandts</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Morra</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>von Lilienfeld-Toal</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hertenstein</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wattad</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>L&#x000fc;bbert</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>H&#x000e4;nel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schmitz</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Link</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kropp</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Rambaldi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>La Nasa</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Luppi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ciceri</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Finizio</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Venditti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fabbiano</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>D&#x000f6;hner</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sauer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ganser</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Amadori</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mandelli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>D&#x000f6;hner</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ehninger</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Schlenk</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Platzbecker</surname>
                <given-names>U</given-names>
              </name>
              <collab>Gruppo Italiano Malattie Ematologiche dell'Adulto</collab>
              <collab>German-Austrian Acute Myeloid Leukemia Study Group</collab>
              <collab>Study Alliance Leukemia</collab>
            </person-group>
            <article-title>Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.</article-title>
            <source>N Engl J Med</source>
            <year>2013</year>
            <month>Jul</month>
            <day>11</day>
            <volume>369</volume>
            <issue>2</issue>
            <fpage>111</fpage>
            <page-range>111-21</page-range>
            <pub-id pub-id-type="pmid">23841729</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27807.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>T&#x000f8;stesen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>&#x000d8;stg&#x000e5;rd</surname>
                <given-names>LSG</given-names>
              </name>
              <name>
                <surname>Kjeldsen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Stentoft</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>N&#x000f8;rgaard</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>[Successful treatment of acute promyelocytic leukaemia without chemotherapy and blood transfusion].</article-title>
            <source>Ugeskr Laeger</source>
            <year>2018</year>
            <month>Jan</month>
            <day>15</day>
            <volume>180</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">29336300</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
